Home / Resources / Preclinical resources

临床前

最新资源

Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human

Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human

网络研讨会点播

Drug-Drug Interaction (DDI) Calculator

药物相互作用 (DDI) 计算器

事实资料表

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development

Securing Pimicotinib Approval: How Abbisko Therapeutics Successfully Completed its NMPA and FDA Submissions with Pinnacle 21 Enterprise

Securing Pimicotinib Approval: How Abbisko Therapeutics Successfully Completed its NMPA and FDA Submissions with Pinnacle 21 Enterprise

精选资源

Securing Pimicotinib Approval: How Abbisko Therapeutics Successfully Completed its NMPA and FDA Submissions with Pinnacle 21 Enterprise

Securing Pimicotinib Approval: How Abbisko Therapeutics Successfully Completed its NMPA and FDA Submissions with Pinnacle 21 Enterprise

Upcoming preclinical webinars

网络研讨会

The Road to First-in-Human: Model-Informed Decisions from Discovery to First Dose

Oct 27, Nov 10

网络研讨会

Application of PBPK Modeling Tools in Biopharmaceutics

2026 年 10 月 29 日 – 10:00 am – 11:00 am JST

网络研讨会

Explore Smarter, Faster PK/PD with Phoenix

2026 年 11 月 3 日 – 10-11 AM ET/CET/JST

Latest preclinical blogs

All Preclinical - Blog

美国 FDA MIDD 配对试点计划如何帮助赞助商

揭秘临床 DDI 研究：精准测量代谢产物

细胞疗法开发的主要考虑因素

支持生物等效性和仿制药审批的 PBPK 建模

The future is now: Virtual clinical trials transforming drug development

Phoenix UGM 2024: A day of innovation and collaboration

在以下活动中与我们的专家会面

AAPS 2026 PharmSci 360

2026 年 10 月 25 - 28 日

Pharmacometrics Approach Group in Japan 2026

2026 年 11 月 13 日

American College of Toxicology 2026 Annual Meeting

November 15 - 18, 2026 – San Antonio, TX – Booth 719

All preclinical resources

2nd Model-Informed Drug Development Summit

Certara Products, Certara Services, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Therapeutic Specialties, Conference

Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human

Biologics, Certara Services, Drug Development, Modeling and Simulation - QSP, On-Demand Webinar

药物相互作用 (DDI) 计算器

Drug Development, Drug-Drug Interactions (DDI), Model Informed Drug Development, Fact Sheet

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development

Modeling and Simulation - QSP, Publication

Securing Pimicotinib Approval: How Abbisko Therapeutics Successfully Completed its NMPA and FDA Submissions with Pinnacle 21 Enterprise

Certara Products - Pinnacle 21, Case Study

Get the Presentation: Building Investor-Ready Biotech Strategies

Drug Development, Drug Development Support, Guide

Enable AI to Access your PK Data: What’s New in Integral 7.1

Certara Products - Phoenix, Clinical Pharmacology, Modeling and Simulation - PK/PD, Webinar

From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs

Certara Products - Certara IQ, Certara Products - Simcyp, Infectious Disease, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - QSP, Oncology/Hematology, Publication

Modeling effective doses of therapeutic antibodies targeting clustered surface receptors

Biologics, Certara Services, Immuno-oncology, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Oncology/Hematology, Publication

Model-Informed Strategies for ADC Development

ADC, Biologics, Certara Services, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Therapeutic Specialties, White Paper

When EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosing

Certara Services, Drug Development, Model Informed Drug Development, Oncology, Pharmacometrics, Publication

External Data Accelerator: Your standards-first team and technology for conformant vendor data

Certara Products - Pinnacle 21, Certara Services, Data Standards, Fact Sheet

1
2
3
……
83
›

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software